User:Intercalate Repro/sandbox

This is the user sandbox of Intercalate Repro. A user sandbox is a subpage of the user's user page. It serves as a testing spot and page development space for the user and is not an encyclopedia article. Create or edit your own sandbox here.

Other sandboxes: Main sandbox | Template sandbox

Finished writing a draft article? Are you ready to request review of it by an experienced editor for possible inclusion in Wikipedia? Submit your draft for review!

Breast Cancer Presentation

HER2 Breast Cancer

Function and expression ^[1]

HER2 has no known direct activating ligand^[2]

Gene amplification ^[3]

Trastuzumab ^[4]

Image 1 ^[5]

Image 2 ^[6]

Image 3 ^[7]

Image 4 ^[8]

Image 5 ^[9]

References

^ Olayioye, Monilola A (2001). "Update on HER-2 as a target for cancer therapy: Intracellular signaling pathways of ErbB2/HER-2 and family members". Breast Cancer Research. 3 (6): 385–389. doi:10.1186/bcr327. ISSN 1465-5411. PMID 11737890.{{cite journal}}: CS1 maint: unflagged free DOI (link)
^ Iqbal, Nida; Iqbal, Naveed (2014). "Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications". Molecular Biology International. 2014: 1–9. doi:10.1155/2014/852748. ISSN 2090-2182.{{cite journal}}: CS1 maint: unflagged free DOI (link)
^ "HER2 Status: Tests, Treatments, and More". Breastcancer.org. 2019-03-09. Retrieved 2019-09-29.
^ Mitri, Zahi; Constantine, Tina; O'Regan, Ruth (2012). "The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy". Chemotherapy Research and Practice. 2012. doi:10.1155/2012/743193. ISSN 2090-2107. PMC 3539433. PMID 23320171.{{cite journal}}: CS1 maint: unflagged free DOI (link)
^ Pohlmann, Paula R.; Mayer, Ingrid A.; Mernaugh, Ray (2009-12-15). "Resistance to Trastuzumab in Breast Cancer". Clinical Cancer Research. 15 (24): 7479–7491. doi:10.1158/1078-0432.CCR-09-0636. ISSN 1078-0432. PMID 20008848.
^ Lin, Nancy U.; Winer, Eric P. (2007-03-15). "Brain Metastases: The HER2 Paradigm". Clinical Cancer Research. 13 (6): 1648–1655. doi:10.1158/1078-0432.CCR-06-2478. ISSN 1078-0432. PMID 17363517.
^ "HER2 and Herceptin". www.aboutcancer.com. Retrieved 2019-09-29.
^ "Breast Cancer Ribbon PNG Transparent Images | PNG All". Retrieved 2019-09-29.
^ Muthuswamy, Senthil K (April 2011). "Trastuzumab resistance: all roads lead to SRC". Nature Medicine. 17 (4): 416–418. doi:10.1038/nm0411-416. ISSN 1078-8956.

[1] Olayioye, Monilola A (2001). "Update on HER-2 as a target for cancer therapy: Intracellular signaling pathways of ErbB2/HER-2 and family members". Breast Cancer Research. 3 (6): 385–389. doi:10.1186/bcr327. ISSN 1465-5411. PMID 11737890.{{cite journal}}: CS1 maint: unflagged free DOI (link)

[2] Iqbal, Nida; Iqbal, Naveed (2014). "Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications". Molecular Biology International. 2014: 1–9. doi:10.1155/2014/852748. ISSN 2090-2182.{{cite journal}}: CS1 maint: unflagged free DOI (link)

[3] "HER2 Status: Tests, Treatments, and More". Breastcancer.org. 2019-03-09. Retrieved 2019-09-29.

[4] Mitri, Zahi; Constantine, Tina; O'Regan, Ruth (2012). "The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy". Chemotherapy Research and Practice. 2012. doi:10.1155/2012/743193. ISSN 2090-2107. PMC 3539433. PMID 23320171.{{cite journal}}: CS1 maint: unflagged free DOI (link)

[5] Pohlmann, Paula R.; Mayer, Ingrid A.; Mernaugh, Ray (2009-12-15). "Resistance to Trastuzumab in Breast Cancer". Clinical Cancer Research. 15 (24): 7479–7491. doi:10.1158/1078-0432.CCR-09-0636. ISSN 1078-0432. PMID 20008848.

[6] Lin, Nancy U.; Winer, Eric P. (2007-03-15). "Brain Metastases: The HER2 Paradigm". Clinical Cancer Research. 13 (6): 1648–1655. doi:10.1158/1078-0432.CCR-06-2478. ISSN 1078-0432. PMID 17363517.

[7] "HER2 and Herceptin". www.aboutcancer.com. Retrieved 2019-09-29.

[8] "Breast Cancer Ribbon PNG Transparent Images | PNG All". Retrieved 2019-09-29.

[9] Muthuswamy, Senthil K (April 2011). "Trastuzumab resistance: all roads lead to SRC". Nature Medicine. 17 (4): 416–418. doi:10.1038/nm0411-416. ISSN 1078-8956.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]